On May 12th, the biaseparations.com website will be retired and migrated to sartorius.com. Learn more about our combined offering today!

Adenovirus vector manufacturing platform using CIMmultus QA assures the supply of safe vaccines

Hana Jug

Cell & Gene Therapy Insights 2021; 7(8), 1125

Abstract:

Downstream processing remains one of the main bottlenecks in adenoviral vector manufacturing. At BIA Separations, a Sartorius company, we offer a platform for purification of adenoviral vaccines using market-leading CIM® monolithic chromatographic columns and an analytical toolbox for process monitoring in adenoviral vaccine production.

Discover more.